Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Geron intends to divest stem cell programs to BioTime; finalized

Executive Summary

Geron Corp. (developing oncology therapeutics) signed a non-binding letter of intent to divest to stem cell technology firm BioTime Inc.’s newly established BioTime Acquisition Corp. (BAC) IP and assets covering its human embryonic stem cell programs.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Contract
    • Product Purchase
    • Includes Equity
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register